Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Brain Res Mol Brain Res ; 32(1): 116-24, 1995 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-7494449

RESUMO

Recent investigations have demonstrated internucleosomal DNA fragmentation in ischemic neuronal tissue. This type of fragmentation is characteristic of programmed cell death or apoptosis and suggests that neuronal death in stroke may be more complex than simple necrotic death. The present experiments provide a detailed examination of the regional localization and time course for apoptotic DNA fragmentation in the cerebral cortex following focal cerebral ischemia. Spontaneously hypertensive rats were subjected to permanent right middle cerebral artery occlusion and the cerebral cortices were examined for evidence of DNA fragmentation using electrophoretic, flow cytometric, and histological approaches. An electrophoretic examination of cortical DNA at 24 h after the occlusion indicated that the majority of nucleosomal ladders were in the transition zone or penumbra and the core of the infarction, with no fragmentation apparent in the contralateral normal cortex. A flow cytometric analysis of DNA fragmentation in intact cells revealed a similar pattern, with increased fragmentation observed in ischemic cortex vs. the contralateral cortex. Saggital sections taken 1.5 mm lateral to midline were collected from animals at 1, 4, and 24 h after the infarction and DNA fragmentation was examined histologically by terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labeling (TUNEL) staining. Quantitative analysis of these sections indicated that DNA fragmentation can be observed in the anterior and central area of the infarctions as soon as 1 h after the occlusion and that the extent and magnitude of the fragmentation increases at 4 and 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)


Assuntos
Apoptose/genética , Doenças Arteriais Cerebrais/genética , Córtex Cerebral/patologia , DNA/química , Ataque Isquêmico Transitório/genética , Animais , Doenças Arteriais Cerebrais/patologia , Infarto Cerebral/etiologia , Infarto Cerebral/patologia , Doença Crônica , Constrição , Citometria de Fluxo , Processamento de Imagem Assistida por Computador , Ataque Isquêmico Transitório/patologia , Ratos , Ratos Endogâmicos SHR , Coloração e Rotulagem
2.
Toxicol Pathol ; 18(4 Pt 2): 651-60, 1990.
Artigo em Inglês | MEDLINE | ID: mdl-2093225

RESUMO

After 2 days of dosing, platelet counts progressively declined in dogs treated orally with 30 mg/kg/day of the antidepressant compound MDL 19,660 for 8 days. Accompanying the decrease in platelet counts was an increase in both large and vacuolated degenerating platelets. Upon cessation of dosing, the platelet counts returned to levels equal to or exceeding predosing levels within 4-7 days. Co-administration with aspirin, a known antiaggregating agent, had no protective effect on the drug-induced thrombocytopenia. In vitro testing of normal canine platelets in the presence of MDL 19,660 further revealed that spontaneous aggregation did not occur and that ADP-induced aggregation was inhibited. Drug-related platelet loss was also not prevented by the co-administration of prednisone, a steroid with immunosuppressive effects and inhibitory properties against reticuloendothelial cell phagocytosis of platelets. The results of the present investigation indicate that MDL 19,660 may produce in the dog a reversible thrombocytopenia in the form of vacuolar degeneration and subsequent destruction of the platelet by means other than aggregation or steroid-responsive mechanisms.


Assuntos
Antidepressivos/toxicidade , Trombocitopenia/induzido quimicamente , Triazóis/toxicidade , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/ultraestrutura , Cães , Feminino , Agregação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Prednisona/farmacologia , Trombocitopenia/patologia , Vacúolos/efeitos dos fármacos
3.
Exp Mol Pathol ; 64(1): 41-51, 1997 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9203508

RESUMO

In situ hybridization analysis provides a means to qualitatively study the heterogeneity of primary tumors and metastases based on the types of genes transcribed. In this study, we have tested some parameters for quantitative analysis of in situ hybridizations with paraffin-embedded human breast tumors and measured mRNA levels for the angiogenic protein, vascular endothelial growth factor (VEGF). VEGF mRNAs were highly tumor specific, with the highest levels near necrotic regions within the tissues (0.1 to 2.7 dpm/mm2). Normal cells within the tissue sections did not have detectable levels of VEGF mRNA. For comparison, tumor levels of c-myc (4 to 46 dpm/mm2) and glyceraldehyde-3-phosphate dehydrogenase mRNAs (48 to 214 dpm/mm2) were measured. The mRNAs for both of these genes were more broadly expressed across the tissue sections. The hybridization pattern for VEGF mRNAs was consistent with hypoxia-induced VEGF mRNA steady-state levels and supports the hypothesis that oxidative stress regulates VEGF expression in breast tumors.


Assuntos
Neoplasias da Mama/química , Fatores de Crescimento Endotelial/análise , Linfonodos/química , Linfocinas/análise , RNA Mensageiro/análise , Biomarcadores Tumorais , Neoplasias da Mama/patologia , Primers do DNA/química , Fatores de Crescimento Endotelial/genética , Feminino , Gliceraldeído-3-Fosfato Desidrogenases/análise , Humanos , Hibridização In Situ , Linfonodos/patologia , Metástase Linfática , Linfocinas/genética , Proteínas Proto-Oncogênicas c-myc/análise , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa